The Upcoming Decade To See An Upswing In The Human Insulin Market At A CAGR Of 12.4%

The healthcare vertical is being driven at the consumers’ pace like never before. In other words, the requirements and goals on their part are driving innovation in every arm of the healthcare vertical. On-demand interactions between clinicians and patients all over the world are being asked for. As such, the healthcare vertical is bound to witness higher strides in the next 10 years. The Human Insulin Market is all set to incorporate the ongoing as well as future trend.

According to a new market report published by Persistence Market Research “Global Market Study on Human Insulin: Asia Pacific to Witness fastest Growth by 2020,” the global human insulin market was valued at USD 24,332.6 million in 2014 and was expected to grow at a CAGR of 12.4% from 2014 to 2020, to reach an estimated value of USD 49,197.3 million in 2020.

Globally, the human insulin market is witnessing significant growth due to increasing prevalence of diabetes and increasing awareness among people about diabetes care. In addition, technological advancements in insulin delivery devices and increasing prevalence of lifestyle related disorders such as obesity are also driving the growth of the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/3308

Some of the major players in the human insulin market:

  • Novo Nordisk A/S.
  • Eli Lilly and Company.
  • Sanofi.
  • Biocon.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Adocia, Merck & Co., Inc.
  • Pfizer, Inc.
  • Wockhardt.
  • Julphar.
  • Bristol-Myers Squibb Company.
  • GlaxoSmithKline Plc.
  • Oramed Pharmaceuticals, Inc

However, uneven pricing and limited access to human insulin in emerging countries such as Brazil, India, and China are inhibiting the growth of the human insulin market. In addition, strict regulatory requirements for drug approval are also restraining the growth of the market.

In North America, increasing prevalence of diabetes with growing age and availability of advanced human insulin infusion devices are driving the use of human insulin in the market.

In addition, increasing prevalence of lifestyle associated disorders such as obesity is also boosting the growth of the human insulin market in this region. For instance, according to the Centers for Diseases Control and Prevention (CDC), a U.S.-based national public health institute, over one-third children and adolescents were obese in 2012 in the U.S.

In Europe, the human insulin market is driven by rising aging population and increasing prevalence of diabetes. In addition, in Germany the market is evolving due to rising prevalence of diabetes and increasing awareness among people about diabetes care. However, in Asia-Pacific the growth for human insulin is much higher than developed countries due to increasing prevalence of diabetes and increasing government initiatives for improving healthcare.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0Shares